PL1863495T3 - Sól wapniowa 1,6:2,3:4,5-tripirofosforanu mioinozytolu jako efektor allosteryczny hemoglobiny w leczeniu raka - Google Patents

Sól wapniowa 1,6:2,3:4,5-tripirofosforanu mioinozytolu jako efektor allosteryczny hemoglobiny w leczeniu raka

Info

Publication number
PL1863495T3
PL1863495T3 PL06738715T PL06738715T PL1863495T3 PL 1863495 T3 PL1863495 T3 PL 1863495T3 PL 06738715 T PL06738715 T PL 06738715T PL 06738715 T PL06738715 T PL 06738715T PL 1863495 T3 PL1863495 T3 PL 1863495T3
Authority
PL
Poland
Prior art keywords
tripyrophosphate
myo
inositol
calcium
sodium salt
Prior art date
Application number
PL06738715T
Other languages
English (en)
Inventor
Claude Nicolau
Jean-Marie Lehn
Konstantina C Fylaktakidou
Ruth Greferath
Original Assignee
Normoxys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Normoxys Inc filed Critical Normoxys Inc
Publication of PL1863495T3 publication Critical patent/PL1863495T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65746—Esters of oxyacids of phosphorus the molecule containing more than one cyclic phosphorus atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL06738715T 2005-03-18 2006-03-17 Sól wapniowa 1,6:2,3:4,5-tripirofosforanu mioinozytolu jako efektor allosteryczny hemoglobiny w leczeniu raka PL1863495T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66349105P 2005-03-18 2005-03-18
PCT/US2006/009682 WO2006102060A1 (en) 2005-03-18 2006-03-17 Calcium salt of myo-inositol 1,6:2,3:4,5 tripyrophosphate as an allosteric effector of hemoglobin
EP06738715.9A EP1863495B1 (en) 2005-03-18 2006-03-17 Calcium and sodium salt of myo-inositol 1,6:2,3:4,5 tripyrophosphate for treating cancer

Publications (1)

Publication Number Publication Date
PL1863495T3 true PL1863495T3 (pl) 2015-06-30

Family

ID=37024136

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06738715T PL1863495T3 (pl) 2005-03-18 2006-03-17 Sól wapniowa 1,6:2,3:4,5-tripirofosforanu mioinozytolu jako efektor allosteryczny hemoglobiny w leczeniu raka

Country Status (8)

Country Link
US (1) US20060241086A1 (pl)
EP (1) EP1863495B1 (pl)
JP (1) JP5028405B2 (pl)
CA (1) CA2601641A1 (pl)
DK (1) DK1863495T3 (pl)
ES (1) ES2532591T3 (pl)
PL (1) PL1863495T3 (pl)
WO (1) WO2006102060A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2828206B1 (fr) * 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
EP1503768B1 (en) 2002-04-29 2015-10-28 NormOxys, Inc. Inositol pyrophosphates, and use thereof
US20060106000A1 (en) * 2004-07-06 2006-05-18 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
US20060258626A1 (en) * 2004-07-06 2006-11-16 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
US7745423B2 (en) * 2004-07-06 2010-06-29 NormOxys, Inc Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin
CA2636089A1 (en) * 2006-01-06 2007-07-19 Oxyplus, Inc. Use of inositol-tripyrophosphate in treating tumors and diseases
CA2674048A1 (en) * 2006-12-29 2008-07-10 Normoxys, Inc. Cyclitols and their derivatives and their therapeutic applications
EP2152085A4 (en) * 2007-05-01 2012-05-23 Normoxys Inc COMPLEMENTATION OR REPLACEMENT OF ERYTHROPOIETIN
AU2008356891A1 (en) * 2008-05-30 2009-12-03 Normoxys, Inc. Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin
EP2451459B1 (en) * 2009-07-07 2017-11-22 Normoxys, Inc. Method of reducing multi-drug resistance using inositol tripyrophosphate
US20140142052A1 (en) * 2012-05-17 2014-05-22 Normoxys, Inc. Phosphorylated polyols, pyrophosphates, and derivatives thereof having biological activity
JP6642478B2 (ja) 2017-02-22 2020-02-05 株式会社デンソー 燃料噴射装置

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5330979A (en) * 1984-10-23 1994-07-19 Perstorp Ab Method of treating renal disorders with inositoltriphosphate
US5407924A (en) * 1984-10-23 1995-04-18 Perstorp Ab Method of treating pain using inositol triphosphate
SE465951B (sv) * 1984-10-23 1991-11-25 Perstorp Ab Isomer av inositoltrifosfat foeretraedesvis i saltform foer anvaendning som terapeutiskt eller profylaktiskt medel samt kompositioner daerav
US5023248A (en) * 1984-10-23 1991-06-11 Perstorp Ab Method of treating diabetes with inositol triphosphate
US5015634A (en) * 1986-04-16 1991-05-14 Perstorp Ab Method of treating tissue damage with inositol triphosphate
SE465305B (sv) * 1986-04-16 1991-08-26 Perstorp Ab Anvaendning av inositolfosfat foer framstaellning av ett laekemedel
US5545632A (en) * 1984-10-23 1996-08-13 Perstorp Ab Method of treating retroviral disease
US5135923A (en) * 1986-04-16 1992-08-04 Perstorp Ab Method of treating cardiovascular diseases
US5057507A (en) * 1986-04-16 1991-10-15 Perstorp Ab Method of alleviating bone damage with inositoltriphosphate
US5274161A (en) * 1986-11-26 1993-12-28 Perstorp Ab Derivatives of cyclohexane
US4924023A (en) * 1987-05-29 1990-05-08 E. I. Du Pont De Nemours And Company Phosphorylated inositols
US4873355A (en) * 1987-05-29 1989-10-10 E. I. Du Pont De Nemours And Company Process for regioselectively preparing phosphorylated inositols and other cyclitols
US5082833A (en) * 1988-06-30 1992-01-21 Shamsuddin Abulkalam M Reduction of cell proliferation and enhancement of nk-cell activity
US5260472A (en) * 1992-01-29 1993-11-09 The Board Of Governors For Higher Education State Of Rhode Island And Providence Plantations Efficient chemoenzymatic synthesis of D-myo-inositol 1,4,5-triphosphate, D-myo-inositol 1,3,4-triphosphate, and D-myo-inositol 1,3,4,5-tetraphosphate
US5260287A (en) * 1992-05-11 1993-11-09 Board Of Regents, The University Of Texas System Polyphosphorylated organic compounds: compositions useful in protecting biological tissues
US5866548A (en) * 1993-04-09 1999-02-02 The Regents Of The University Of California Caged membrane-permeant inositol phosphates
SE502989C2 (sv) * 1993-11-22 1996-03-04 Perstorp Ab Användning av en inositoltrisfosfatester för beredning av läkemedel
SE503122C2 (sv) * 1993-11-22 1996-03-25 Perstorp Ab Användning av en inositoltrisfosfatester för behandling av inflammatoriska tillstånd
US6949517B1 (en) * 1996-06-24 2005-09-27 Matti Siren Method of treating inflammatory, tissue repair and infectious conditions
US5880099A (en) * 1996-09-20 1999-03-09 The Regents Of The University Of California Inositol polyphosphates and methods of using same
US5977078A (en) * 1996-09-20 1999-11-02 The Regents Of The Univesity Of California Inositol polyphosphate derivatives and methods of using same
CN1145489C (zh) * 1996-09-20 2004-04-14 加利福尼亚大学董事会 肌醇多磷酸酯衍生物及其使用方法
US6221856B1 (en) * 1999-02-03 2001-04-24 Inologic, Inc. Inositol derivatives for inhibiting superoxide anion production
IT1306133B1 (it) * 1999-04-22 2001-05-30 Sigma Tau Healthscience Spa Composizione comprendente una carnitina ed un inositolfosfato, utilequale integratore dietetico o medicamento.
EP1272201B1 (de) * 2000-04-12 2004-11-24 Bitop Aktiengesellschaft Für Biotechnische Optimierung Verwendung von kompatiblen soluten als substanzen mit radikalfangenden eigenschaften
US7084126B1 (en) * 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
US20020142995A1 (en) * 2000-08-01 2002-10-03 Nicolau Yves Claude Ammonium salts of hemoglobin allosteric effectors, and uses thereof
WO2002010177A1 (en) * 2000-08-01 2002-02-07 Gmp Companies, Inc. Ammonium salts of inositol hexaphosphate and uses thereof
CA2430190A1 (en) * 2000-11-21 2002-05-30 Alexis Traynor-Kaplan Inositol derivatives for increasing chloride secretion and inhibiting inflammation
EP1435969A4 (en) * 2001-09-20 2006-08-16 Inologic Inc METHOD FOR MODULATING THE ABSORPTION OF SODIUM IONS IN EPITHELIAL CELLS
EP1503768B1 (en) * 2002-04-29 2015-10-28 NormOxys, Inc. Inositol pyrophosphates, and use thereof
AU2003239973A1 (en) * 2002-06-14 2004-01-19 Gmp Oxycell, Inc. Sterols bearing pendant allosteric effectors of hemoglobin, and uses thereof
EP1628984A1 (en) * 2003-03-27 2006-03-01 Inologic, Inc. Camphanylidene and phenylalkyl inositol polyphosphate compounds, compositions, and methods of their use
ES2232302B1 (es) * 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
US20060106000A1 (en) * 2004-07-06 2006-05-18 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
CA2636089A1 (en) * 2006-01-06 2007-07-19 Oxyplus, Inc. Use of inositol-tripyrophosphate in treating tumors and diseases

Also Published As

Publication number Publication date
ES2532591T3 (es) 2015-03-30
CA2601641A1 (en) 2006-09-28
EP1863495A1 (en) 2007-12-12
EP1863495A4 (en) 2010-06-02
WO2006102060A1 (en) 2006-09-28
JP5028405B2 (ja) 2012-09-19
EP1863495B1 (en) 2015-02-18
US20060241086A1 (en) 2006-10-26
DK1863495T3 (en) 2015-04-20
JP2008535804A (ja) 2008-09-04

Similar Documents

Publication Publication Date Title
PL1863495T3 (pl) Sól wapniowa 1,6:2,3:4,5-tripirofosforanu mioinozytolu jako efektor allosteryczny hemoglobiny w leczeniu raka
IL188430A0 (en) Treatment of tumors
ZA200800907B (en) Treatment of cancer
IL229975A0 (en) Pharmaceutical compounds containing arsenoic acid, its sodium salt and its antecedents for the treatment of organ cancer and its metastases
EP1959931A4 (en) COMPOSITIONS AND METHODS FOR THE DERMAL TREATMENT OF PAIN
PL1960370T3 (pl) Pochodne pirydiazynynowe do leczenia nowotworów
GB0503380D0 (en) Tissue treatment system
IL187085A0 (en) Combination therapy comprising diaryl ureas for treating diseases
ZA200708575B (en) Methods and compositions for treating or preventing cancer
ZA200800006B (en) Composition for treating skin lesions
IL185258A (en) Oligodeoxyribonucleotides for use in the treatment of angiogenesis-dependent tumors in human
EP1855662A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
HK1164767A1 (en) Compounds and methods for the treatment of cancer
EP1867640A4 (en) MEANS FOR TREATING SOLID TUMORS
EP1984327A4 (en) IMPROVED METHOD FOR THE PRODUCTION OF CILASTATIN AND ITS SODIUM SALT
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
GB0520067D0 (en) Treatment of cancer
HK1225304A1 (zh) 治療骨癌
IL226362A0 (en) compounds, and methods for treating cancer
GB0503382D0 (en) Tissue treatment system
ZA200805522B (en) Dioxoiane dérivates for the treatment of cancer
ZA200706871B (en) Treatment of metastasized tumors
GB0505203D0 (en) Skin composition treatment
GB0507685D0 (en) Cancer treatment
IL198344A0 (en) Use of mtki 1 for treating or preventing bone cancer